Humanizing Technologies, Inc. – Trademark Portfolio
Entity Type: 03
Humanizing Technologies, Inc. holds 7 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 35 (Advertising & Business) — 4 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 2 Nice Classification classes. Currently, 2 trademarks are registered and 1 is pending. Notable registered marks include CAVO CODER and CAVO HEALTH. The owner is based in Indianapolis, IN.
6325 Digital Way, Suite 330
Indianapolis, IN 46278
Showing of trademarks Trademarks
Trademark Classifications
Humanizing Technologies, Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Advertising; business management; business administration; office functions
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does Humanizing Technologies, Inc. have?
Humanizing Technologies, Inc. has 7 U.S. trademarks filed with the USPTO. Of these, 2 registered, 1 pending, 3 abandoned, 1 cancelled.
What trademark classes does Humanizing Technologies, Inc. file in?
Humanizing Technologies, Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 35 (Advertising & Business), Class 42 (Computer & Scientific). Class 35 covers advertising; business management; business administration; office functions.
What are Humanizing Technologies, Inc.'s most well-known trademarks?
Humanizing Technologies, Inc.'s registered trademark portfolio includes well-known marks such as CAVO CODER and CAVO HEALTH. These are among 2 currently registered trademarks in the portfolio.
What is Humanizing Technologies, Inc.'s trademark registration success rate?
Humanizing Technologies, Inc. has a 33% trademark registration rate, with 2 out of 6 resolved applications resulting in successful registration. Currently, 1 application is pending review.